BIOMAT Database Logo BIOMAT Database Logo

[Pharmacokinetic and clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics]. 1989

T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
Department of Pediatrics, School of Medicine, Kurume University.

Cefpodoxime proxetil (CPDX-PR, CS-807) is a new oral cephem derivative drug in which carboxylic acid was esterified to the 4-position of CPDX (oxime type cephem antibiotic). CPDX-PR is hydrolyzed mainly with esterase in intestinal wall and CPDX exists as an active form in body fluid. While there are numerous study reports using CPDX-PR in tablet forms in Japan, the dry syrup formula for pediatric use was newly developed. The dry syrup of CPDX-PR was orally administered 20 minutes after meal to the 6 boys of ages from 8 years and 1 month to 10 years and 10 months, with doses of 3 and 6 mg/kg, respectively, for 3 cases each. Serum concentrations and urinary concentrations and recovery rate of the drug were investigated. In addition to the above, the clinical and bacteriological studies were performed in a total of 105 cases consisting of children with ages ranging from 2 months to 11 years and 8 months, upon administering an average dose of 3.4 mg/kg, 3 to 4 times per day (96 cases of 3 times and 9 cases of 4 times). The 105 cases included 13 cases of pharyngitis, 21 cases of tonsillitis, 4 cases of acute bronchitis, 6 cases of pneumonia, 1 case of pleurisy, 13 cases of scarlet fever, 41 cases of urinary tract infection, 3 cases of posthitis and 3 cases of bacillary dysentery. Drug sensitivity test was performed for the following strains: (i) Strains retained by our department; 52 strains of Streptococcus pyogenes, 18 strains of Streptococcus agalactiae, and 11 strains of Bordetella pertussis, and (ii) strains isolated from cases to which CPDX-PR was administered; 2 strains of Staphylococcus aureus, 8 strains of S. pyogenes, 2 strains of Haemophilus influenzae, 10 strains of Escherichia coli, and 1 strain of Proteus mirabilis. Drug sensitivities of the strains retained by our department were tested with the inoculum sizes of 10(8) and 10(6) cfu/ml for R-3746 (Na-salt of CPDX), cefaclor (CCL), cephalexin (CEX), amoxicillin (AMPC), and methicillin (DMPPC), and those against strains separated from the cases to which CPDX-PR was administered were tested with the same inoculum sizes for R-3746, CCL, CEX, cefadroxil, ampicillin (ABPC), DMPPC and cloxacillin (MCIPC). Adverse reactions and abnormal clinical laboratory test results were also examined.(ABSTRACT TRUNCATED AT 400 WORDS)

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007564 Japan A country in eastern Asia, island chain between the North Pacific Ocean and the Sea of Japan, east of the Korean Peninsula. The capital is Tokyo. Bonin Islands
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Clinical studies on cefpodoxime proxetil dry syrup in the field of pediatrics].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Pharmacokinetic, bacteriological and clinical studies on cefpodoxime proxetil in the field of pediatrics].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[The clinical study of cefpodoxime proxetil dry syrup preparation in the pediatric field].
September 1994, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[A clinical study on cefpodoxime proxetil dry syrup in pediatric infections].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Pharmacokinetic, bacteriological and clinical evaluation of cefpodoxime proxetil in pediatrics].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
Clinical evaluation of cefpodoxime proxetil dry syrup in pediatric cutaneous bacterial infection.
November 1995, Journal of chemotherapy (Florence, Italy),
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
[Clinical studies of cefpodoxime proxetil in pediatric field].
July 1989, The Japanese journal of antibiotics,
T Motohiro, and K Oda, and M Aramaki, and A Kawakami, and K Tanaka, and T Koga, and Y Sakata, and T Fujimoto, and K Yokochi, and F Yamashita
A multi-institutional study on clinical effectiveness of cefpodoxime proxetil dry syrup in childhood infections.
November 1995, Journal of chemotherapy (Florence, Italy),
Copied contents to your clipboard!